We wish a happy and healthy holiday to everyone who has trusted SOM Biotech during this challenging year marked by the Covid-19 pandemic. Thank you, especially to the entire team, whose hard work has been essential in such a demanding year. We wish you a safe and Merry Christmas and a happy and prosperous 2021.
SOM Biotech ends the notable year 2020 with relevant advances in its pipeline. The company started 2020 with positive results from the Phase 2a proof-of-concept to evaluate the safety and efficacy of SOM3355, an inhibitor of the Vesicular Monoamine Transporter-2 (VMAT2), in Huntington´s disease (HD) patients with chorea. The clinical efficacy of SOM3355 in reducing …
SOM Biotech announces its participation at the BIO-Partnering at JP Morgan Healthcare Conference 2021, being held virtually on January 11th – 15th. The conference, a leading virtual partnering and business development initiative for the biotechnology industry organized by Biotechnology Innovation Organization, provides a One-on-One partnering platform to give companies access to potential strategic partners and …
European Biotechnology Life Science and Industry Magazine published the article “A pioneering real AI drug discovery technology” describing the approach of SOM Biotech. The current COVID-19 pandemic situation has shown that repurposing drugs can be crucial for delivering new treatments to patients with agility. Existing drugs can be developed to bring fast, safe and cost-effective …
La Vanguardia published a press release: “The future of biotechnology: lower-cost treatments in a short period of time”. You can find a short overview of the press release below. SOM Biotech has designed a computational Artificial Intelligence-based method to analyze molecular structures and select the best option after performing more than 2.5 million comparisons in …
SOM Biotech announces its participation at the Drug Discovery Innovation Programme event 2020, being held virtually on November 17th. The conference will be chaired by Kevin McAllister, PhD, MBA Chief Scientific Officer. As a keynote speaker, Maria Zimina, PhD. MBA, Business Development Manager, will present “AI Evolutionary Algorithms for the Identification of Non-Structural Analogs: Case …
SOM Biotech presents its drug candidate SOM3355 for the Chorea in Huntington Disease at the XIX Pharma-Biotech Cooperation conference, November 12th 2020. The conference, an initiative of Farmaindustria – the National Trade Association of the Spanish based pharmaceutical industry – allows companies previously selected for their contribution to innovation, to present their drug development projects to …
SOM Biotech will attend the “BIO-Europe 2020” convention on October 26th – 29th, which will take place digitally due to the pandemic situation. Raúl Insa, CEO of SOM Biotech: “BIO-Europe 2020 is one of the most relevant partnering events for the life science sector. We look forward to meeting with potential partners and qualified investors …
SOM Biotech announces today that it will present in silico and in vitro results regarding Eravacycline for the treatment of SARS-CoV-2 during a virtual poster presentation at the IDWeek 2020. The poster is entitled “Repurposing of Eravacycline for the Treatment of SARS-CoV-2 Infections”. It outlines pre-clinical data demonstrating that Eravacycline is a potent inhibitor of …
SOM Biotech has attended the virtual V Workshop “Duchenne and the Brain” organized by the Duchenne Parent Project Spain on September 7th, on the occasion of the World Duchenne Awareness Day 2020. Gal·la Pericot, R&D Manager of SOM Biotech: “The Duchenne Parent Project Spain is a valuable initiative to encourage collaboration among R&D groups that work on finding …